

**This PANNA newsletter will also be available at the website: [www.pannastudy.com](http://www.pannastudy.com)**

A newsletter will be issued once per 3 months to update you on the status of the study and inclusions.

### Investigators Meeting in Glasgow Monday November 8 17:00-18:30 during Tenth International Congress on Drug Therapy in HIV Infection (7-11 November 2010)

Location: Ness room (Seminar Suite on the first floor at the SECC).

See <http://www.hiv10.com/>

for information on the conference.

You are all invited to participate in this meeting to get updated on the project, to discuss the project and the planning. If you are not able to come, another member of your group is very welcome to attend. In that case please provide us with the name and e-mail address.

Would you be so kind to let me know before **October 1st** whether you will participate? Unfortunately PANNA will not be able to fund any travel expenses or conference fee for this meeting.

### List of compounds under investigation

#### panna

Etravirine, Intelence, ETV  
Emtricitabine, Emtriva or FTC  
Tenofovir, Viread, TDF  
Atazanavir, Reyataz, ATV  
Fosamprenavir, Telzir, FPV  
Darunavir, Prezista, DRV  
Tipranavir, Aptivus, TPV  
Indinavir, Crixivan, IDV  
Raltegravir, Isentress, RAL  
Enfuvirtide, Fuzeon, T-20  
Maraviroc, Celsentri, MVC  
Efavirenz, Stocrin, EFV\*  
\*UK/Ireland only

### Amendment

The second amendment to the protocol has been approved in The Netherlands and in the UK. In Germany/Ireland this was included in the submitted protocol.

### Centres

All centres in *The Netherlands; Spain; UK; Italy* are open for inclusion.

*Germany*: 4 centres open for inclusion.

*Ireland*: submission done.

*Portugal*: working on submission.

*France*: working on submission.

*Belgium*: working on submission.



*Canada*: a grant has been assigned, ethics submission will start.

Other centres (*Switzerland; Spain; Italy; Poland*) will follow and will be contacted by Angela as soon as the above mentioned centres have started.

### Inclusions

14 subjects signed informed consent.

No extra inclusions since July 2<sup>nd</sup>, due to the vacation period?



During my holiday (till August 20<sup>th</sup>) you can contact David in case of questions.

Angela Colbers  
Project manager

E-mail: [A.Colbers@akf.umcn.nl](mailto:A.Colbers@akf.umcn.nl)  
[HIVPharmacology@akf.umcn.nl](mailto:HIVPharmacology@akf.umcn.nl)  
Radboud University Nijmegen Medical  
Centre, Internal postal code 864,  
Department of Pharmacy,  
P.O. Box 9101, 6500 HB Nijmegen  
Phone: + 31 (0)24 - 361 64 05  
Fax: + 31 (0)24- 366 87 55